An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

Mario Cazzola, Josuel Ora, Francesco Cavalli, Paola Rogliani, Maria Gabriella Matera

Abstract: Several mAbs have been tested or are currently under clinical evaluation for the treatment of COPD. They can be subdivided into those that aim to block specific pro-inflammatory and pro-neutrophilic cytokines and chemokines, such as TNF-α, IL-1β, CXCL8 and IL-1β, and those that act on T2-mediated inflammation, respectively, by blocking IL-5 and/or its receptor, preventing IL-4 and IL-13 signaling, affecting IL-33 pathway and blocking TSLP. None of these approaches has proved to be effective, probably because in COPD there is no dominant cytokine or chemokine and, therefore, a single mAb cannot be effective on all pathways. With a more in-depth understanding of the numerous pheno/endotypic pathways that play a role in COPD, it may eventually be possible to identify those specific patients in whom some of these cytokines or chemokines might predominate. In this case, it will be possible to implement a personalized treatment, but the use of each mAb will only be reserved for a very limited number of subjects.

Keywords: COPD, monoclonal antibodies, pheno/endotypic pathways, anti–T1-mediated inflammation mAbs, anti–T2-mediated inflammation mAbs

Introduction

Although COPD is a disorder characterized by the presence of chronic inflammation that is predominantly neutrophilic, there is a rather large proportion of patients with a predominantly eosinophil-mediated inflammation or in whom neutrophilic inflammation is combined to varying degrees with eosinophilic inflammation. Other inflammatory cells including macrophages and CD4+ and CD8+ T lymphocytes are also involved, but the extent of their participation varies depending on the patient’s endotype. In addition, inflammatory cells are variably distributed in the bronchial tissue between and within individuals with COPD and over time, which is certainly critical when treating a patient with COPD, but unfortunately still poorly studied. Table 1

Unfortunately, inflammation in COPD lungs responds poorly to corticosteroid treatment. For this reason, over the past two decades, pharmacological research has been moving toward finding new anti-inflammatory pharmacological approaches to treat COPD patients more adequately. The focus was on finding new targets that inhibit the recruitment and activation of inflammatory cells involved in COPD. This is leading to the synthesis of new drugs that should block the inflammatory mediators that recruit or activate these cells or are released by them. Unfortunately,
Table 1 Trials That Have Evaluated or are Evaluating mAbs in COPD

<table>
<thead>
<tr>
<th>Classes of mAbs</th>
<th>mAbs</th>
<th>Effects</th>
<th>Ongoing Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeting specific pro-inflammatory and pro-neutrophilic cytokines and chemokines in COPD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α inhibitors</td>
<td>Etanercept</td>
<td>Reduction in COPD hospitalizations. No beneficial effect for the treatment of AECOPDs but in patients with &lt;2% eosinophils at baseline showed a possible better response than with prednisone. No beneficial effects.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Infliximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti–CXCL8</td>
<td>ABX-CXCL8</td>
<td>Improvement in dyspnoea, but not in lung function or health status.</td>
<td></td>
</tr>
<tr>
<td>Anti–IL-1β</td>
<td>Canakinumab</td>
<td>Lack of efficacy on the risk of AECOPDs, lung function, and health status.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MEDI8986</td>
<td>Lack of efficacy on the risk of AECOPDs, lung function, and health status.</td>
<td></td>
</tr>
<tr>
<td>Anti–IL-17A</td>
<td>CNTO 6785</td>
<td>Only a small improvement in FEV1% predicted.</td>
<td></td>
</tr>
<tr>
<td>Targeting T2-mediated inflammation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti–IL-5</td>
<td>Mepolizumab</td>
<td>Reduction of the rate of moderate and severe AECOPDs in those with higher levels of blood eosinophils. In individuals with blood eosinophil counts ≥150 cells/µL at screening or ≥300 cells/µL in the prior year, reduction of AECOPDs requiring corticosteroid treatment especially in the presence of increased blood eosinophil counts, but not of those requiring antibiotics. Reduction of the rate of moderate and severe AECOPDs in those with higher levels of blood eosinophils. A history of three or more AECOPDs in the past 12 months, baseline postbronchodilator FEV1 less than 40% and postbronchodilator response of 15% or more predict the treatment effect in individuals with baseline blood eosinophil count ≥220 cells/µL under triple therapy.</td>
<td>A Phase III trial ongoing to confirm the benefits of mepolizumab as add-on treatment to optimized maintenance COPD therapy in COPD patients experiencing frequent AECOPDs and characterized by eosinophil levels. A Phase II study evaluating whether starting mepolizumab at the time of a hospitalisation for an AECOPD in patients with significant eosinophilia will result in a reduction in readmission to hospital in a high-risk population. A Phase III trial evaluating the efficacy and safety of mepolizumab on annualized rate of moderate or severe AECOPDs in patients with moderate to very severe COPD with a history of ≥2 moderate and/or severe AECOPDs in the previous year and elevated peripheral blood eosinophils (≥300/µL) despite receiving triple therapy for at least 3 months and ICS-based dual inhaled treatment for the rest of the year. A Phase II trial testing whether in patients who have an elevated eosinophil count at the time of exacerbation, a single injection of benralizumab alone or in combination with prednisolone will improve clinical response compared with prednisolone alone.</td>
</tr>
<tr>
<td></td>
<td>Benralizumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti–IL13/anti–IL4</td>
<td>Dupilumab</td>
<td>It does not influence AECOPD rate versus placebo in patients with COPD and a history of exacerbations despite ICS and at least one long-acting bronchodilator inhaler medication.</td>
<td>A Phase III trials assessing its efficacy, safety, and tolerability in patients with moderate-to-severe COPD with type 2 inflammation.</td>
</tr>
<tr>
<td></td>
<td>Lebrikizumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti–TSLP</td>
<td>Tezepelumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(Continued)</td>
</tr>
</tbody>
</table>
many of these approaches have failed to reach the clinical development stage or have failed in the clinic.8 Nevertheless, the improved understanding of the inflammatory process underlying COPD is suggesting the use of biologic agents or biological response modifiers, which act by neutralizing or modulating the function of certain inflammatory mediators such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-8, IL-13, IL-18, IL-23, IL-33, eotaxin-1 (CCL-11), thymic stromal lymphopoietin (TSLP), and transforming growth factor (TGF)-β, in order to achieve a more specific anti-inflammatory action.9 This should implement targeted treatment that improves disease control and decreases exacerbation rates.

Most biological therapies are based on the administration of antibodies against these mediators or their receptors (table 1), although inhibitors, mostly of kinases, are also used.9 Monoclonal antibodies (mAbs) offer several advantages such as high affinity and specificity binding against a wide variety of proteins depending on the target, relative metabolic stability that allows them to remain active for long periods of time with a duration of action of weeks or even months, and low toxicity because their degradation products are amino acids and therefore are not converted into toxic metabolites.10

<table>
<thead>
<tr>
<th>Classes of mAbs</th>
<th>mAbs</th>
<th>Effects</th>
<th>Ongoing Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti–IL-33</td>
<td>Itpekimab</td>
<td>No reduction of the annualized rate of moderate-to-severe AECOPDs but in former smokers with COPD significant reduction of the frequency of AECOPDs and improvement of lung function.</td>
<td>Phase III trials evaluating its efficacy compared with placebo on the annualized rate of moderate-or-severe AECOPDs over a 52-week placebo-controlled treatment period in former smokers with moderate-to-severe COPD. A Phase II trial evaluating its impact on the rate of AECOPDs. A Phase II proof of concept trial assessing its effects compared with placebo on pulmonary function after 12 week-treatment in patients with moderate to severe COPD and chronic bronchitis.</td>
</tr>
</tbody>
</table>

Targeting Specific Pro-Inflammatory and Pro-Neutrophilic Cytokines and Chemokines in COPD

In neutrophil-associated COPD with activation of the inflammasome, T1 and T17 immunity is the most common phenotype.11,12 Several cytokines are thought to drive neutrophilic inflammation, such as TNF-α, IL-8, IL-17, and IL-23. Human bronchial epithelial cells also express IL-6, IL-17 and IL-22/IL-22R. IL-1β and TNF levels are increased in COPD and are associated with macrophage activation and neutrophilic inflammation.11,12 Macrophages are recruited with activation of the NOD-like receptor protein-3 (NLRP3) inflammasome and caspase-1-dependent release of pro-inflammatory IL-1-like cytokines IL-1α, IL-1β, IL-33, and IL-18.12 Although COPD is primarily characterized by neutrophilic inflammation, studies on targeted biologic therapy for neutrophilic inflammation have been disappointing to date.

TNF-α Inhibitors

A recent systematic review and meta-analysis performed to evaluate the correlation between TNF-α level and COPD reported that TNF-α level was increased in patients with COPD compared with healthy controls.13 Several pollutants, including cigarette smoke, induce TNF-α production by alveolar macrophages, neutrophils, T cells, mast cells, and epithelial cells.14 TNF-α augments neutrophil chemotaxis and migration by inducing IL-8 expression and increasing endothelial adhesion molecules.15 Furthermore, it is a potent activator of NF-κB, capable of amplifying the inflammatory response.16 However, TNF-α inhibitors have shown only limited clinical efficacy. In controlled trials, infliximab, an immunoglobulin (Ig)G mAb that can quickly form stable complexes with the human soluble or membrane form of TNF, and thus terminate the biological activity of TNF, had no beneficial effects in patients with mild, moderate, or severe phenotype.
COPD.\textsuperscript{17,18} Conversely, in patients with rheumatoid arthritis and COPD, etanercept, a receptor blocker that binds to free-floating and cell-bound TNF, and not infliximab, reduced COPD hospitalizations, but only 16 of 1205 patients (1.3\%) in the study were on etanercept.\textsuperscript{19} In any case, in a double-blind randomized controlled trial, etanercept had no beneficial effect for the treatment of acute exacerbations of COPD (AECOPDs) although patients treated with etanercept and with <2\% eosinophils at baseline showed a possibly better response than those treated with prednisone.\textsuperscript{20}

The reason for the failure of anti–TNF therapies in patients with COPD is presumably because other proinflammatory cytokines drive the inflammatory process.\textsuperscript{15} However, preclinical studies suggest that TNF-α inhibitors could reverse corticosteroid insensitivity by restoring the broad attenuation effects of corticosteroids on inflammation and airway remodelling\textsuperscript{21} and, also, when combined with corticosteroids, they could induce synergistic effects in controlling airway remodelling.\textsuperscript{22}

**Anti–CXCL8 mAbs**

IL-8 is a pro-inflammatory chemokine from the CXC family. It is also known as CXCL8 and is a chemokine with potent neutrophil chemotactic and activation properties.\textsuperscript{23} Patients with COPD have high levels of CXCL8 in sputum and BAL fluid.\textsuperscript{23} However, results from a Phase II pilot study in COPD patients with ABX-CXCL8, a fully human mAb that recognized only free CXCL8, suggested that neutralization of CXCL8 may improve dyspnoea, but fails to improve lung function or health status.\textsuperscript{24} It has been suggested that the clinical failure of this mAB is likely due to the active form of CXCL8 is bound to proteoglycans on the endothelial surface.\textsuperscript{4}

PA401 or dnCXCL8, which is a modified recombinant human CXCL8 characterized by an increased binding affinity to glycosaminoglycans that allows it to displace endogenous CXCL8 from glycosaminoglycans expressed at the site of inflammation, can reduce BAL neutrophils and systemic inflammatory markers in a mouse lung inflammation model.\textsuperscript{25} HuMax-IL8 (previously known as BMS-986253), a fully human IgG\textsubscript{11} mAb that binds to free IL-8, has previously been tested in a Phase I clinical trial on cancer patients\textsuperscript{26} and is currently the object of an ongoing Phase 2 clinical trial in patients affected by severe COVID-19 (NCT04347226). Both PA401 and HuMax-IL8 have not been evaluated in patients with COPD.

**Anti–IL-1β mAbs**

The IL-1 family consists of two related polypeptides, IL-1α and IL-1β that bind to the same primary receptor IL-1R1, which is expressed by almost all cell types, and can recruit and/or activate a variety of immune cells and immunocompetent cells, such as macrophages, endothelial cells, neutrophils, and epithelial cells.\textsuperscript{27} The activity of IL-1β in the lung induces a phenotype with typical COPD features, consisting of pulmonary inflammation, emphysema, and airway fibrosis.\textsuperscript{27} IL-1β secretion is increased in stable and exacerbating COPD\textsuperscript{28} and is likely involved in the initiation and persistence of inflammation. In COPD IL-1β serum level correlates with clinical aspects of disease severity.\textsuperscript{29}

Because specific pharmacologic blockade of IL-1 activity in COPD may be relevant for limiting inflammation and exacerbations in COPD, canakinumab, which is an anti–IL-1β mAb, and MEDI8986, a fully human IgG\textsubscript{2} mAb that binds selectively to IL-1R1, were tested in patients with COPD; however, the results demonstrated an acceptable safety profile but a lack of efficacy at least with regard to impact on the risk of AECOPDs, lung function, and health-related quality of life (HRQoL).\textsuperscript{30} Nevertheless, it has been highlighted the need for better stratification and targeting of specific disease cohorts and for studies with specific mAbs against IL-1α and IL-1β using lung-specific biomarkers to understand whether targeting these cytokines is a viable therapeutic approach for patients with COPD.\textsuperscript{31} In addition, it has been suggested that interfering with IL-1 may reduce mucosal inflammatory responses to microbes, which could predispose patients to respiratory tract infections and pneumonia.\textsuperscript{32}

**Anti–IL-17A mAbs**

The IL-17 family of cytokines has six members, of which IL-17A and IL-17F are highly homologous and bind to a complex receptor of IL-17RA and IL-17RC, so that they share similar biological effects.\textsuperscript{33} IL-17A and IL-17F are involved in COPD pathophysiology, although a study found evidence of increased production of IL-17A but not IL-17F in the bronchial submucosa of COPD patients.\textsuperscript{34} IL-17 activates many signalling pathways, which in turn leads to the production of many other cytokines (such as IL-6, IL-1β, TNF-α, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], and TGF-β) and chemokines (including IL-8 and monocyte chemotactrant protein [MCP1]) from many alveolar cell types (endothelial cells, epithelial
cells, and macrophages). The increase in the production of IL-17A causes neutrophil recruitment, leading to chronic inflammation. IL-17A can also promote airway remodeling by increasing TGF-β1 and inhibiting cell autophagy in inflammatory lung tissue. IL-17 airway activity positively correlates with disease severity in COPD patients.

Even though different models of experimental COPD suggest that IL-17A drives lung inflammation and lung damage, targeting IL-17A has, so far, not been proven to be useful in the treatment of stable COPD patients. CNTO 6785, a mAb that binds to human IL-17A, caused a small improvement in forced expiratory volume in 1 s (FEV1)% predicted in patients with moderate-to-severe symptomatic COPD, but failed to show any statistically or clinically significant difference in primary or secondary end points between the intervention and placebo arms. In addition, there were more protocol defined AECOPD's in the CNTO 6785 arm compared with placebo at week 16 (18 vs 11).

A number of anti–IL-17A and anti–IL-17RA mAbs are under development to decrease neutrophil recruitment and airway inflammation. However, most studies have been and are aimed at testing the effects of these mAbs on asthma rather than COPD, likely because IL-17 secreted by Th17 cells, plays a key role in the pathogenesis of neutrophilic asthma, which is unresponsive to high dose inhaled corticosteroids (ICSs), and probably to precision novel anti-IgE, and IL mAb therapies. A blockade of IL-17RA resulting in the inhibition of the effects of both IL-17A and IL-17F has been attempted in patients with severe asthma using brodalumab, which is a mAb that targets IL-17RA. Although it did not induce any improvement in lung function, symptoms, or QoL, the study population was not screened for neutrophils in sputum or mediators of the IL-17 pathway. A study (NCT01902290) that aimed to assess whether brodalumab was safe and effective compared to placebo as measured by changes in Asthma Control Questionnaire (ACQ) composite scores in inadequately controlled asthma subjects with high bronchodilator reversibility but not selected based on matching endotype was stopped due to lack of efficacy. Conversely, secukinumab, a fully human anti–IL-17A of the IgG1k isotype, seemed to work in those patients suffering from not adequately controlled severe asthma despite high doses of ICSs and LABAs. These patients had low IgE (<150/μL) and increased nasal epithelial neutrophilic inflammation. Responders were defined as >5% change from baseline of percent predicted FEV1. However, treatment with secukinumab was terminated, as it was not effective in the target population.

CCJM112, a novel fully human anti–IL-17A IgG1k mAb that, in contrast to secukinumab, binds with similar affinity to both human IL-17A and IL-17A, has already been studied in a phase II trial in patients with uncontrolled severe asthma and low blood IgE and eosinophil levels (NCT03299686). The study has been completed, but results have not been published yet.

Brodalumab, secukinumab and CCJM112 have not yet been tested in patients with COPD. The lack of interest in evaluating these mAbs in COPD is surprising. As there is documentation that a signature of IL-17-associated airway inflammation is upregulated in approximately a third of COPD participants and is associated with distinct inflammatory, physiologic, and clinical features. It has been suggested that targeting IL-17 in COPD may therefore be therapeutically useful if it is aimed at well-characterised neutrophilic patients who may respond well to these drugs, possibly identified by nasal sampling performed to detect those with high IL-17 levels. However, it must be highlighted that secukinumab was unable to inhibit ozone-induced acute neutrophilic airway inflammation in healthy volunteers. Furthermore, targeting the IL-17 pathway may increase the risk of AECOPD by diminishing host defense. Neutralizing IL-17 activity can induce immunosuppression, which is problematic in patients with COPD given their susceptibility to pulmonary infections. Not insignificant, in this regard, is the concern that blocking the IL-17/IL-23 axis, which plays an important role in defending the lungs against bacterial infections through the release of antimicrobial peptides from airway epithelial cells, may cause reduced immunity to infections.

**Targeting T2-Mediated Inflammation Using mAbs**

In COPD, patients may have increased eosinophil counts in peripheral blood and/or sputum that might predict a clinical response to ICSs, with an improvement in post-bronchodilator FEV1 following treatment. Although the T2 immune response, which encompasses eosinophilic inflammation and is mediated by IL-4, IL-5 and IL-13, typically decreases with aging, tobacco smoking may attenuate the age-related decrease in total serum IgE levels and eosinophilic inflammation in populations with and also without asthma. This immunologic picture in a...
smoking subject is termed asthma-COPD overlap (ACO), although controversy exists regarding the precise definition of ACO also because there are patients with neutrophil predominant ACO.\textsuperscript{50} The high percentage of patients with COPD who show a T2 inflammation explains the interest in evaluating the effects of specific mAbs able to interfere with eosinophils.\textsuperscript{6} However, it should always be considered that blood eosinophil counts can be variable in individual COPD patients.\textsuperscript{51} Consequently, classifying COPD as noneosinophilic, with intermediate eosinophilic picture, or clearly eosinophilic considering the three thresholds <100 cells/mm\textsuperscript{3}, 100–299 cells/mm\textsuperscript{3}, and ≥300 cells/mm\textsuperscript{3}, respectively, suggested by the Global Initiative for Chronic Obstructive Lung Disease\textsuperscript{52} may be incorrect if repeated counts of eosinophils in the blood over time are not performed.

**Anti–IL-5 mAbs**

IL-5 modulates the proliferation, maturation, and activation of eosinophils and eosinophilic airway inflammation and appears to modulate the development and functions of human basophils and mast cells owing to the common expression of several crucial receptors in these cells.\textsuperscript{53} Its biological effects are mediated by its selective interaction with the IL-5 receptor (IL-5R), consisting of a specific α subunit (IL-5Rα) and a non-specific βc heterodimer.\textsuperscript{53}

It has been reported that sputum concentrations of IL-5 are correlated with sputum eosinophil numbers in COPD patients with eosinophilia.\textsuperscript{54} Furthermore, soluble IL-5Rα is increased during virus-induced AECOPDs.\textsuperscript{55} Since eosinophils rapidly undergo apoptosis in the absence of IL-5, it is believed that blocking IL-5 may be a potential therapeutic approach to prevent or dampen eosinophil-mediated inflammation.\textsuperscript{56} The efficacy and safety of mepolizumab, a humanized mAb of the IgG\textsubscript{1k} class that blocks free IL-5, and benralizumab, a fully humanized afucosylated IgG\textsubscript{1k} mAb that binds to a specific epitope within the extracellular domain on IL-5Rα, which is in close proximity to the IL-5 binding site and thus inhibits IL-5R signalling, independent of ligand, which are currently approved for treatment of severe eosinophilic asthma, have now been examined in large clinical trials in the eosinophilic COPD population. Both mepolizumab and benralizumab had a similar safety profile that was not significantly different compared to placebo.\textsuperscript{30}

A recent Cochrane systematic review that included six studies involving a total of 5542 participants concluded that mepolizumab and benralizumab probably reduce the rate of moderate and severe AECOPDs in the highly selected group of people who have both COPD and higher levels of blood eosinophils (patients with blood eosinophils at the higher end of the normal range as well as those with true blood eosinophilia).\textsuperscript{57}

However, it should be noted that it is still unknown which subpopulation of COPD patients is most likely to respond to anti–IL-5 mAbs,\textsuperscript{58} although they are most likely to be those with a higher disease burden and a higher degree of eosinophilic inflammation. A pre-specified meta-analysis of data of individuals with blood eosinophil counts ≥150 cells/µL at screening or ≥300 cells/µL in the prior year from two trials that looked at mepolizumab in COPD showed that mepolizumab had primarily reduced AECOPDs requiring corticosteroid treatment especially in the presence of increased blood eosinophil counts, while the effect on exacerbations requiring antibiotics was less pronounced.\textsuperscript{59} An analysis of two Phase 3 clinical trials testing the effects of benralizumab in patients with moderate to very severe COPD found that a history of three or more AECOPDs in the past 12 months, baseline postbronchodilator FEV\textsubscript{1} less than 40% and postbronchodilator response of 15% or more were the strongest and most consistent baseline clinical characteristics that appeared to predict the treatment effect with this mAb in individuals with baseline blood eosinophil count ≥220 cells/µL and who were receiving triple therapy.\textsuperscript{60}

However, the interest in correctly positioning anti–IL-5 Abs in the treatment of COPD has not yet died down. A Phase III trial is ongoing to confirm the benefits of mepolizumab as add-on treatment to optimized maintenance COPD therapy in COPD patients experiencing frequent AECOPDs and characterized by high eosinophil levels (NCT04133909 or MATINEE), while a Phase II study is evaluating whether starting mepolizumab at the time of a hospitalisation for an AECOPD in patients with significant eosinophilia will result in a reduction in readmission to hospital (NCT04075331 or COPD-HELP).

A Phase III trial that aims to evaluate the efficacy and safety of benralizumab on annualized rate of moderate or severe AECOPDs in patients with moderate to very severe COPD with a history of ≥2 moderate and/or severe AECOPDs in the previous year and elevated peripheral blood eosinophils (≥300/µL) despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the rest of the year is ongoing (NCT04053634 or RESOLUTE). In contrast, a Phase II trial is testing whether in patients who
have an elevated eosinophil count at the time of exacerbation, a single injection of benralizumab alone or in combination with prednisolone will improve clinical response compared with prednisolone alone (NCT04098718 or ABRA).

In any case, the presence of resident human eosinophils in the lungs that are independent of IL-5 prevents massive removal of eosinophils from the airways from inducing any significant clinical benefit in many patients with COPD. Therefore, we cannot exclude that airway eosinophilia in COPD may be driven in an IL-5-independent manner and be different from that found in asthma.

**Anti–IL13/Anti–IL4 mAbs**

IL-4 and IL-13, which are made by mast cells, T2 cells, and innate lymphoid 2 cells (ILC2s), bind to the type 2 receptor complex, IL-4Rα/IL-13Rα1, on airway epithelial cell, smooth muscle cells, eosinophils, and mast cells. IL-4 also binds to the type 1 receptor complex found on T cells, which consists of IL-4Rα and a γc-chain. This leads to upregulation of T2 responses with accumulation of eosinophils and downregulation of T1 responses. IL-13 directly affects airway contractility. It also increases mucus production, and by stimulating periostin release from airway epithelial cells, may contribute to remodelling.

Experimentally in a transgenic mouse model, it has been observed that eosinophil-derived IL-13 stimulates alveolar macrophages to produce matrix metalloprotease (MMP)-12 and, thus, plays a role in alveolar destruction. At the same time, it was documented that patients with eosinophilic COPD and coexisting emphysema, pulmonary eosinophilia was associated with elevated levels of MMP-12, predictive of emphysema.

Two pivotal studies (NCT03930732 or BOREAS and NCT04456673 or NOTUS) are assessing the efficacy, safety, and tolerability of dupilumab, a fully human IgG4 mAb that targets IL4Rα thus inhibiting signalling of both IL-4 and IL-13, in patients with moderate-to-severe COPD with type 2 inflammation.

Lebrikizumab, a humanised mAb that binds to soluble IL-13 and blocks activation of IL-4Rα and IL-13Rα1 heterodimers, has been evaluated in patients with COPD and a history of exacerbations despite ICS and at least one long-acting bronchodilator inhaler medication (NCT02546700 or VALETA). The full results are yet to be released, but preliminary data suggest that they do not influence AECOPD rate versus placebo. There is no information on the use of tralokinumab, a human IgG4 mAb that neutralizes IL-13 and prevents interaction with its receptor, in COPD patients.

**Anti–TSLP mAbs**

Thymic stromal lymphopoietin (TSLP), an IL-7-like cytokine, is an upstream epithelial T2 cytokine known to exert multipotential pathogenic effects also beyond T2 inflammation. It initiates the intracellular T2 signalling by binding to its high-affinity heterodimer receptor complex, which consists of its specific receptor, TSLPR, and an IL-7Rα subunit in cells co-expressing TSLPR and IL-7Rα. TSLP initially binds to TSLPR, followed by recruiting of the IL-7Rα chain. TSLP is produced by airway epithelial cells during inflammation and induces T2 immune response by directly stimulating T cells, mast cells, and natural killer cells and indirectly by activation of CD11c+ dendritic cells located within the lung epithelium that then migrate to the lymph nodes where they prime CD4+ T cells to produce T2 inflammatory cytokines.

Constitutive and in vivo expression of TSLP has been documented in the airway smooth muscle of COPD patients. It is likely that this TSLP expression could influence immune regulation by interacting with and influencing local immune cells in the COPD airways. Furthermore, viruses can induce overproduction of TSLP in COPD epithelial cells, suggesting a role for TSLP in AECOPDs. However, also T1 cytokines can induce TSLP production in COPD and it has been speculated that dendritic cell-derived TSLP acts as an important molecular checkpoint to limit IL-1β-mediated effector responses through a negative feedback loop that may limit the magnitude of the inflammatory response to injury.

Tezepelumab, a human IgG2 mAb that binds to TSLP, preventing its interaction with the TSLP receptor complex, is under investigation in a phase IIa, multicentre, double-blind, randomised trial in patients with moderate to very severe COPD receiving triple inhaled maintenance therapy, and having had 2 or more documented AECOPDs in the 12 months prior the enrolment (NCT04039113 or COURSE).

**Targeting IL-33 Pathway**

IL-33, an alarmin cytokine from the IL-1 family, is released from the epithelium due to damage to epithelial cells and exerts its pro-inflammatory biological functions via its receptor, which is a heterodimeric complex that
comprises suppression of tumorigenicity 2 (ST2) and IL-1 receptor accessory protein (IL-1RAcP).\textsuperscript{72} The resulting signal leads to the induction of transcription of downstream inflammatory and anti-inflammatory genes. IL-33 has been implicated in eosinophil recruitment to the airway and maturation in the bone marrow largely via ILC2, and thus it promotes the ILC2 response, which secretes a large amount of IL-5 and IL-13 in allergic inflammation.\textsuperscript{73}

It is believed that IL-33 could play a role in the pathogenesis and progression of COPD because substantial increases in IL-33 levels have been documented in serum or plasma and sputum as well as in lung biopsy specimens, epithelial and endothelial cells of COPD patients.\textsuperscript{74} The expression of IL-33 and the ST2 receptor increases in this disorder probably due to the inducing action of cigarette smoke, with levels that are associated with the degree of airway and systemic inflammation.\textsuperscript{75} In effect, a reduction in COPD risk associated with \textit{IL33} (rs146597587) loss of function and, on the contrary, gains of function in \textit{IL33} and \textit{IL1RL1} variants with increased risk have been documented.\textsuperscript{73}

A Phase II study has evaluated the impact of itepekimab, an anti–IL-33 human IgG\textsubscript{4} mAb, as an add-on to the standard of care on the annualized rate of moderate-to-severe AECOPDs over up to 52 weeks of treatment.\textsuperscript{76} Compared with placebo, itepekimab did not significantly reduce the annualized rate of moderate-to-severe AECOPDs. However, in former smokers with COPD, it significantly reduced the frequency of exacerbations and improved lung function, again compared with placebo.

Another Phase II trial has evaluated the impact of MSTT1041A, an anti-ST2 mAb, administered subcutaneously by an infusion pump at 490 mg every 4 weeks over a 48-week treatment period, on the rate of AECOPDs (NCT03615040 or COPD-ST2OP), but no result has been posted.

Other RCTs are ongoing. Itepekimab is now under further investigation in two Phase III trials to evaluate its efficacy compared with placebo on the annualized rate of moderate-or-severe AECOPDs over a 52-week placebo-controlled treatment period in former smokers with moderate-to-severe COPD (NCT04701983 or AERIFY-1 and NCT04751487 or AERIFY-2). MEDI 3506, another anti–IL-33 mAb, is in a Phase II proof-of-concept trial that is assessing its effects compared with placebo on pulmonary function after 12 weeks of treatment in patients with moderate-to-severe COPD and chronic bronchitis (NCT04631016 or FRONTIER-4).

**Administration of mAbs by Inhalation**

It is possible that the low efficacy of mAbs is, at least in part, due to the fact that they are large molecules that are administered systemically and reach the lung only in a small percentage of the administered dose.\textsuperscript{76,77} It is therefore conceivable that their administration by inhalation may increase the proportion of active drug in the lung with limited passage of the drug into the bloodstream.\textsuperscript{78} However, the pulmonary delivery of mAbs is challenging in terms of aerosol technology and the formulation of biological agents for inhalation.\textsuperscript{76} It is important that mAbs remain stable during aerosolization. It is likely that mesh nebulizers allow for delivery of high amounts of drugs (often required for mAbs) and better preserve the molecular integrity of proteins by being less harsh regarding chemical and physical constraints.\textsuperscript{79} Obviously, the addition of surfactant to maintain the molecular integrity and, thus, the pharmacological activity of mAbs during vibrating net nebulizing is necessary.\textsuperscript{77} It is therefore desirable that trials comparing the effects of a systemically administered mAb with those induced by the same mAb administered by inhalation be performed as soon as possible. However, only mAbs with very high doses potency are suitable for pulmonary delivery because only small volumes of fluid can be administered.\textsuperscript{80}

**Conclusion**

As we have repeatedly pointed out, there are different pheno/endotypes of COPD whose presence makes a personalized therapeutic approach to the COPD patient crucial and the generalization of results of clinical trials that have not considered this issue of no real value.\textsuperscript{6,81,82}

It is likely, therefore, that the lack or near lack of therapeutic effect of the various mAbs tested in different RCTs reflects the complexity of COPD with its numerous pheno/endotypic pathways playing a role in COPD.\textsuperscript{6,82} In fact, in COPD, there is no dominant cytokine or chemokine and, therefore, a single mAb cannot be effective on all pathways. This makes it essential to evaluate these mAbs in specific well-identified pheno/endotypes in which some of these cytokines or chemokines might predominate, such as in eosinophilic COPD.\textsuperscript{6,82}

The redundancy of signal-induced effects, particularly the possibility that other pathways can still induce or maintain the inflammatory state even when a specific pathway is turned off, represents a high critical point that must
always be considered when evaluating the effects of mAbs in COPD. It is the most likely cause of failure when blocking a single specific pathway and is, furthermore, a major obstacle to the development of targeted therapies.

In general, almost all available studies on the use of mAbs in COPD focus on the prevention of AECOPDs. However, there are several other outcomes that also need to be considered when treating a patient with COPD. Cochrane's analysis of anti-IL-5 therapies for COPD has concluded that there was probably little or no difference between the intervention and placebo for quality-of-life measures. Apparently, there is also no major impact of these mAbs on lung function. For other classes of mAbs, information is even more scarce. There is no doubt that in the future it will be necessary to study in detail the impact of mAbs on other key outcomes such as pulmonary function, as important differences may also be detected. For example, an experimental study showed that benralizumab was more potent than mepolizumab in increasing levels of cAMP in the airways, which may mean a different impact on lung function. Another experimental study documented that activation of the IL-4/IL-13 pathway can promote profound airway smooth muscle hyperreactivity, while neither IL-5 nor IL-17A enhanced airway contractile responses. Thus, the impact of blocking these cytokines with mAbs may result in completely different bronchial tone responses.

Although we completely agree that mAbs could be the future of personalized treatment in COPD, we are fully aware that there is a long way to go before they become part of everyday practice in COPD. In any case, our opinion is that mAbs will be reserved for a very limited number of patients suffering from COPD. Perhaps, however, if the therapeutic approach is centered on treatable traits as suggested for the treatment of COPD in general and eosinophilic forms in particular, new studies focusing on outcomes other than exacerbations may provide information that could broaden the range of those who may benefit from these drugs.

Funding
No funding was utilized in the creation of this review.

Disclosure
Professor Mario Cazzola reports grants and personal fees from Almirall, Boehringer Ingelheim, Novartis, and Zambon and personal fees from ABC Farmaceutici, AstraZeneca, Biofutura, Chiesi Farmaceutici, Cipla, Edmond Pharma, GlaxoSmithKline, Lallemand, Menarini, Mundipharma, Ockham Biotech, Pfizer, Sanofi, and Verona Pharma, outside the submitted work. Professor Paola Rogliani reports grants, personal fees, non-financial support from Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis, and her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici Novartis, and Zambon. Professor Maria Gabriella Matera reports grants and personal fees from GlaxoSmithKline, and Novartis and personal fees from ABC Farmaceutici, AstraZeneca, and Chiesi Farmaceutici, outside the submitted work. The authors declare no other competing interests in this work.

References


